Intravitreal bevacizumab (Avastin®) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial

British Journal of Ophthalmology

Volumn 93, Issue 4, 2009, Pages 452-456

  Prager, F ^a   Michels, S ^b   Kriechbaum, K ^a   Georgopoulos, M ^a   Funk, M ^a   Geitzenauer, W ^a   Polak, K ^a   Schmidt Erfurth, U ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RECURRENCE RISK; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETINA VEIN OCCLUSION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 64849111444     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.141085     Document Type: Article

References (22)

1. Cugati S, Wang JJ, Rochtchina E, et al. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 2006;124:726-32.
2. Hayreh SS, Zimmerman B, McCarthy MJ, et al. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001;131:61-77.
3. Blondel J, Glacet-Bernard A, Bayani N, et al. Retinal vein occlussion and hyperhomocysteinemia. J Fr Ophthalmol 2003;26:249- 53.
4. Rath EZ, Frank RN, Shin DH, et al. Risk factors for retinal vein occlusion. A casecontrol study. Ophthalmology 1992;99:509- 14.
5. Koizumi H, Ferrara DC, Brue C, et al. Central vein occlusion case-control study. Am J Ophthalmol 2007;144:858-63.
6. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
7. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271-82.
8. The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M. Ophthalmology 1995;102:1425-33.
9. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005;140:695-702.
10. Karacorlu M, Karacorlu SA, Ozdemir H, et al. Intravitreal triamcinolone acetonide for treatment of serous macular detachment in central vein occlusion. Retina 2007;27:1026-30.
11. Gregori NZ, Rosenfeld PJ, Puliafito CA, et al. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central vein occlusion. Retina 2006;26:889-95.
12. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-9.
13. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-84.
14. Hsu J, Kaiser RS, Sivalingam A, et al. Intravitreal bevacizumab (avastin) in central vein occlusion. Retina 2007;27:1013-9.
15. Rabena MD, Pieramici DJ, Castellarin AA, et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007;27:419-25.
16. Kriechbaum K, Michels S, Prager F, et al. Intravitreal avastin for macular oedema secondary to retinal vein occlusion-a prospective study. Br J Ophthalmol 2008;92:518-22.
17. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9.
18. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-7.
19. Matsumoto Y, Freund KB, Peiretti E, et al. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous oclusive disease. Retina 2007;27:426-31.
20. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 2008;22:42-8.
21. Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Exp Ophthalmol 2006;244:309-15.
22. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644-50.